Mycoplasma pneumoniae is a major cause of pneumonia and accounts for as many as 20% of the total number of cases of pneumonia (6) . The recommended therapy is erythromycin, which is efficacious in reducing the duration of symptoms (19) . Recently , it has been suggested that new macrolides (8, 10) , such as azithromycin, clarithromycin, and roxithromycin, may be used more frequently for respiratory tract infections because of their improved potencies and pharmacokinetic parameters compared with those of erythromycin (10) . Azithromycin is a new azalide antibiotic (7, 15 ) that differs from erythromycin by a methyl-substituted nitrogen at position 9a within the macrocyclic ring. This modification has resulted in improved potency against gram-negative bacteria. Moreover, azithromycin proved to be superior to erythromycin in a mouse pneumococcal model because of these improved pharmacokinetic parameters (1) .
In this study we evaluated the in vitro antimycoplasmal activities of azithromycin, erythromycin, clarithromycin, and roxithromycin. We also tested the in vivo antimycoplasmal efficacies of azithromycin, erythromycin, and clarithromycin in courses of 10 Organisms. Forty clinically isolated strains of M. pneumoniae obtained from 1988 to 1992 at Nagasaki University Hospital and three standard strains, FH, Mac, and M129, which were supplied by M. F. Barile (Food and Drug Administration, Bethesda, Md.), were used for in vitro tests, and the virulent strain M129 at passage level 12 was used for experimental mycoplasmal pneumonia in Syrian golden hamsters.
MIC determinations. MICs were determined by using a modified broth microdilution method (12, 22, 23) with modified Chanock broth medium (3) , which consisted of seven parts PPLO broth without crystal violet (Difco Laboratories, Detroit, Mich.), 2 parts uninactivated horse serum, 1 part 25% fresh yeast extract, 1% glucose, and 0.002% phenol red adjusted to pH 7.8 with 1 N sodium hydroxide. Inocula were 10 CFU/ml. The plates, sealed with plate sealers, were incubated at 37°C in air. In each case, when the color of the medium of the drug-free control changed from red to yellow, the minimal concentration of drug preventing the color change was defined as the MIC. As a control for potential interactions between antibiotics, medium components, and pH, which could potentially affect the observed MICs, the American Type Culture Collection bacterial reference strain Staphylococcus aureus ATCC 29213 (for which MICs of the drugs tested, obtained with Mueller-Hinton broth, have been published [24] ) was inoculated into microtiter plates containing Chanock broth. A positive (growth) control consisting of organisms in broth, a negative (sterility) control consisting of uninoculated broth, and a drug control consisting of broth containing the highest concentration of drug tested were included for each M. pneumoniae strain tested. Infection of hamsters. In vivo activities of macrolides were assessed with a pulmonary infection model using Syrian golden hamsters (2, 20) . Each dosing group consisted of 10 6-week-old male Syrian golden hamsters weighing about 100 g (Japan SLC, Shizuoka, Japan). Five hamsters in each dosing group were sacrificed and submitted for study of viable mycoplasma cells, and the remainder were used for the microscopic pathology study. The lungs of all hamsters were also examined macroscopically when their thoraxes were surgically opened. Hamsters were anesthetized by intraperitoneal injection of ketamine (Sankyo Co., Ltd.) and infected by a peroral intratracheal intubation method described previously (2), with modifications. The hamsters were mounted upside down on a 450 angle from vertical. A bent, blunted 2-in. (ca. 5-cm) 20-gauge Angiocath (Becton Dickinson Vascular Access) was inserted under the glottis into the trachea, and the inner needle was drawn. A 1-ml tuberculin syringe was attached to the outer catheter and moved as far forward as possible. A 0.15-ml aliquot of the organism suspension containing 7.5 x 106 CFU of M. pneumoniae M129 at passage level 12 was inoculated directly into the trachea. Control intratracheal inoculations with India ink verified the limited distribution of the inoculum into the right lung, especially the lower right lobe. For a negative control, broth not containing M. pneumoniae was also inoculated, and no lung lesions were observed microscopically or macroscopically after that inoculation.
Therapeutic plan. The in vivo activities of macrolides against experimentally induced M. pneumoniae pneumonia in hamsters were examined by tube feeding. Oral administration of azithromycin, erythromycin, and clarithromycin (each given at 10 mg/kg once daily for 1 and 3 days and at 15 mg/kg twice daily for 2.5 and 5 days) was started on day 5 after inoculation of M.
pneumoniae.
In groups treated with 10 mg/kg once daily for 1 day, hamsters were sacrificed on days 7, 9, and 11 after infection. In groups treated with 10 mg/kg once daily for 3 days, hamsters were sacrificed on days 9 and 11 after infection. In groups treated with 15 mg/kg twice daily for 2.5 days, hamsters were sacrificed on day 9 after infection. In groups treated with 15 mg/kg twice daily for 5 (17) . M. pneumoniae was not recovered from the plates with the 100 and 10-1 dilutions after azithromycin therapy because of the high concentration of azithromycin remaining in the medium, so colony counts for all therapeutic courses were determined with plates with dilutions of 10-2 or 10-3. Some isolated colonies were identified by inhibition of growth in the presence of anti-M. pneumoniae rabbit serum and by their hemadsorption properties (4) . For the untreated control, oral administration of 5% arabic gum solution was started on day 5 after inoculation of M. pneumoniae and continued for 1 day once only and for 2.5 and 5 days twice daily. After 2 days for each untreated control, five hamsters in each case were sacrificed and their lungs were quantitatively cultured. Before treatment (day 5 after infection), measurement of the number of viable mycoplasma cells in lungs was also done.
Assessment of lung lesions. Counting of viable mycoplasmal cells after therapy was not sufficient for estimating the therapeutic effects of the drugs, so we also tried to estimate the severity of pneumonia microscopically and macroscopically.
(i) Microscopic lung lesions. Five hamsters in each group were sacrificed, and their lungs were fixed by in situ intratra- Fig. 3 ). These criteria were established by modifying the criteria described previously by Barile et al. (2) . This trial was performed blindly by two investigators, and the average score was recorded.
(ii) Macroscopic lung lesions. Lesions in the lung were limited to the right lower lobe, so the severity of pneumonia could be estimated macroscopically by measuring the extent of macroscopic lung lesions in the right lower lobe. Small differences in the extents of macroscopic lung lesions were difficult to distinguish, so the severity of pneumonia was classified into six groups according to the extent of macroscopic lesions, and a ratio representing each group was determined, as follows (see Fig. 6 ): lesion less than one-eighth of the lobe, 0; more than one-eighth and less than one-fourth, 1/8; more than one-fourth and less than one-half, 1/4; more than one-half and less than three-fourths, 1/2; more than three-fourths and less than one, 3/4; and more than one lobe, 1. This trial was also done blindly.
Levels of azithromycin, erythromycin, and clarithromycin in lungs. Concentrations of azithromycin, erythromycin, and clarithromycin in lungs taken from uninfected 6-week-old male Syrian golden hamsters weighing about 100 g were determined.
Samples were taken 0.5, 1, 2, 4, 6, 12, and 24 Fig. 1 . 11 after infection, azithromycin at 10 mg/kg once daily for 1 day and at 10 mg/kg once daily for 3 days was more effective than the corresponding regimens of erythromycin and clarithromycin (P < 0.01). There was a statistically significant difference between results with the early control (day 5 after infection) and the untreated control on day 7 . There was also a statistically significant difference between results with the untreated control on day 7 after infection and the untreated control on day 9 and between results with the untreated control on day 9 and the untreated control on day 11.
Histological evaluations. Data relating to microscopic pathological scores and area ratios of macroscopic lung lesions in the right lower lobe after oral administration of drugs following experimentally induced pneumonia in Syrian golden hamsters are shown in Fig. 2 to 5 . A macroscopic lung lesion (Fig. 6 ) is shown to be composed primarily of cell infiltrations into interalveolar septums when it is observed microscopically (Fig. 2) . Thus, microscopic study was useful mainly for estimating the severity of peribronchial and peribronchiolar lesions, and macroscopic study was useful mainly for estimating the severity of peripheral lesions, which include the interalveo- lar septum and lung alveolus. In microscopic and macroscopic estimations there was no statistically significant difference between the early control (day 5 after infection) and the untreated control on days 7, 9, and 11, which showed that there was no spontaneous microscopic or macroscopic histologic reduction in mycoplasmal pneumonia in the hamsters until day 11 after infection. This result shows that the natural histopathological course of mycoplasmal pneumonia in hamsters was not parallel with the natural course of viable M. pneumoniae numbers in the hamsters' lungs. Microscopic histopathology estimations. On day 7 after infection, compared with the untreated control, azithromycin at 10 mg/kg once daily for 1 day' was effective for reducing microscopic histopathological severity (P < 0.05), whereas erythromycin and clarithromycin were not effective.
On day 9 after infection, compared with the untreated control, azithromycin at 10 mg/kg once daily for 1 day (P < 0.01), at 10 mg/kg once daily for 3 days (P < 0.01), and at 15 mg/kg twice daily for 2.5 days (P < 0.01); erythromycin at 10 mg/kg once daily for 3 days (P < 0.05) and at 15 mg/kg twice daily for 2.5 days (P < 0.05); and clarithromycin at 10 mg/kg once daily for 1 day (P < 0.05), at 10 mg/kg once daily for 3 days (P < 0.01), and at 15 mg/kg twice daily for 2.5 days (P < 0.01) were effective. On day 9 after infection, azithromycin at 10 mg/kg once daily for 1 day (P < 0.01), at 10 mg/kg once daily for 3 days (P < 0.01), and at 15 mg/kg twice daily for 2.5 days (P < 0.01) was more effective than the corresponding regimens of erythromycin and clarithromycin. There were no significant differences among results for azithromycin at 10 mg/kg once daily for 1 day, 10 mg/kg once daily for 3 days, and 15 mg/kg twice daily for 2.5 days on day 9.
On day 11 after infection, compared with the untreated control, azithromycin at 10 mg/kg once daily for 1 day (P < 0.01), at 10 mg/kg once daily for 3 days (P < 0.01), and at 15 mg/kg twice daily for 5 days (P < 0.01); erythromycin at 15 mg/kg twice daily for 5 days (P < 0.05); and clarithromycin at 10 mg/kg once daily for 1 and 3 days (P < 0.05) and at 15 mg/kg twice daily for 5 days (P < 0.05) were effective. On day 11 after infection, azithromycin at 10 mg/kg once daily for 1 day (P < 0.01), 10 mg/kg once daily for 3 days (P < 0.01), and 15 mg/kg twice daily for 5 days (P < 0.05) was more effective than the corresponding regimens of erythromycin and clarithromycin. There were no significant differences among results for azithromycin at 10 mg/kg once daily for 1 day, 10 mg/kg once daily for 3 days, and 15 mg/kg twice daily for 5 days on day 11. Macroscopic histopathology estimations. On day 7 after infection, compared with the untreated control, azithromycin was effective (P < 0.01), whereas erythromycin and clarithtomycin at 10 mg/kg once daily for 1 day were not effective. for reducing macroscopic histopathological severity. On day 9 after infection, compared with the untreated control, azithromycin at 10 mg/kg once daily for 1 day (P < 0.05), at 10 mg/kg once daily for 3 days (P < 0.001), and at 15 mg/kg twice daily for 2.5 days (P < 0.001); erythromycin at 10 mg/kg once daily for 3 days (P < 0.05) and at 15 mg/kg twice daily for 2.5 days (P < 0.001); and clarithromycin at 10 mg/kg once daily for 1 day (P < 0.05), at 10 mg/kg once daily for 3 days (P < 0.001), and at 15 mg/kg twice daily for 2.5 days (P < 0.0005) were effective. On day 9 after infection, all regimens of azithromycin were more effective than the corresponding regimens of erythromycin and clarithromycin (P < 0.05). On day 11 after infection, compared with the untreated control, azithromycin at 10 mg/kg once daily for 1 day (P < 0.0005), at 10 mg/kg once daily for 3 days (P < 0.0005), and at 15 mg/kg twice daily for 5 days (P < 0.0005); erythromycin at 10 mg/kg once daily for 3 days (P < 0.01) and at 15 mg/kg twice daily for 5 days (P < 0.01); and clarithromycin at 10 mg/kg once daily for 1 day (P < 0.05), at 10 mg/kg once daily for 3 On day 11 after infection, all regimens of azithromycin were more effective than the corresponding regimens of erythromycin and clarithromycin (P < 0.01).
Levels of azithromycin, erythromycin, and clarithromycin in hamster lungs. Levels of azithromycin, erythromycin, and clarithromycin in lungs are shown in Table 5 Day 11
After infection FIG. 5 . Course of macroscopic severity of experimentally induced M. pneumoniae pneumonia in hamsters. Results are means for 10 hamsters per group with standard deviations. Column numbers, counting from left to right: 1, early control; 2, untreated control; 3, azithromycin at 10 mg/kg once daily for 1 day; 4, erythromycin at 10 mg/kg once daily for 1 day; 5, clarithromycin at 10 mg/kg once daily for 1 day; 10, azithromycin at 10 mg/kg once daily for 3 days; 11, erythromycin at 10 mg/kg once daily for 3 days; 12, clarithromycin at 10 mg/kg once daily for 3 days; 13, azithromycin at 15 mg/kg twice daily for 2.5 Fourteen-and 16-membered-ring macrolides, such as erythromycin, clarithromycin, roxithromycin, josamycin, and leukomycin, have lower activities than azithromycin against gramnegative bacteria and M. pneumoniae (8, 9, 12) . Although M. pneumoniae is phylogenetically related to gram-positive bacteria and not to gram-negative bacteria, it seems that the susceptibility of M. pneumoniae to macrolides roughly parallels that seen with gram-negative bacteria. In our in vivo study, two different parameters, i.e., viable mycoplasmal cell counts and histopathological severity, were used for estimating efficacies of therapy with azithromycin, clarithromycin, and erythromycin. Histopathological features in humans and hamsters are similar (11), so our in vivo data should be more interesting than those from studies that only count the numbers of M. pneumoniae in order to estimate drug efficacy.
There was no statistically significant histopathological difference between the early control (day 5 after infection) and the untreated control on days 7, 9, and 11, which showed that there was no spontaneous histological reduction in the hamsters' mycoplasmal pneumonia. On the other hand, the number of viable M. pneumoniae cells in hamster lungs on day 7 after infection increased significantly, that on day 9 decreased compared with that on day 7, and that on day 11 also decreased significantly compared with that on day 9 . These results show that the natural histopathological course in the hamsters' mycoplasmal pneumonia was not parallel with the natural course of viable M. pneumoniae numbers in the hamsters' lungs; that is, the histopathological change in the lungs remains after reduction of the number of viable M. pneumoniae cells. On the basis of our therapeutic study, in which erythromycin at 10 mg/kg once daily for 3 days and clarithromycin at 10 mg/kg once daily for 1 day (Table 4) reduced histopathological severities significantly and did not reduce the numbers of mycoplasma cells in lungs on day 9 after infection, macrolide therapy seems to be more effective for reductions in histopathologies than for the reduction of numbers of viable M. pneumoniae cells. This may reflect the mechanism of action of macrolide antibiotics, which is a bacteriostatic activity; that is, macrolides in some concentrations only inhibit the virulence process of M. pneumoniae, which is complex, without killing M. pneumoniae (21) .
Azithromycin was significantly more effective than erythromycin or clarithromycin in the same regimens. Especially at 10 mg/kg once daily for 1 day, only azithromycin was significantly effective in reducing viable mycoplasma cell counts and histopathologies (Table 4) . Good pharmacokinetic activity in hamsters and excellent antimycoplasmal potency are why azithromycin showed greater efficacy than other drugs in the in vivo study using a hamster pulmonary infection model. We cannot prove the efficacy of azithromycin in treating M. pneumoniae pulmonary infection in humans, but it is generally recognized that M. pneumoniae pneumonia in hamsters is similar to that in humans, so we can guess that a smaller dose of azithromycin than of erythromycin or clarithromycin may be effective in M. pneumoniae pneumonia in humans. Our data suggest that clinical studies of macrolides in human patients are warranted.
